Get started
Award

R35 CA197292

Funded outputs count: 84
Funder award ID: R35 CA197292
OpenAlex ID: G5700729068
Integrated Single-Cell Profiling Reveals Dichotomous NK Cell Populations Associated with Immunosuppression in Solid Tumors
2026 · John R. Lozada, Atef Ali, et al. · Cancer Immunology Research · 2
The transcription factor BCL11B drives NK cell cytotoxicity and antitumor activity
2025 · Akhilesh Kumar, Bin Zhang, et al. · The Journal of Immunology · 2
Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting
2025 · John R. Lozada, Andrew Elliott, et al. · Cancer Research Communications · 17
PDF
Pan-Cancer Interrogation of B7-H3 ( CD276 ) as an Actionable Therapeutic Target Across Human Malignancies
2024 · Carly D. Miller, John R. Lozada, et al. · Cancer Research Communications · 32
PDF
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes
2024 · Nicholas A. Zorko, Allison Makovec, et al. · Prostate Cancer and Prostatic Diseases · 29
PDF
Quantification of low-level human cytomegalovirus and Epstein-Barr virus DNAemia by digital PCR
2024 · DeVon N. Hunter-Schlichting, Rachel I. Vogel, et al. · Journal of Virological Methods · 10
Microfluidic Organoid Cultures Derived from Pancreatic Cancer Biopsies for Personalized Testing of Chemotherapy and Immunotherapy
2023 · Daheui Choi, Alan M. Gonzalez‐Suarez, et al. · Advanced Science · 74
PDF
Non-classical HLA-E restricted CMV 15-mer peptides are recognized by adaptive NK cells and induce memory responses
2023 · Nerea Martín Almazán, Benedetta Maria Sala, et al. · Frontiers in Immunology · 11
Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma
2023 · Frank Cichocki, Bin Zhang, et al. · Science Translational Medicine · 48
PDF
NK Cells from Human Cytomegalovirus–Seropositive Individuals Have a Distinct Metabolic Profile That Correlates with Elevated mTOR Signaling
2023 · John R Lozada, Bin Zhang, et al. · The Journal of Immunology · 6
PDF
Clinical outcomes in patients with metastatic castrate‐resistant prostate cancer treated with abiraterone with or without ongoing androgen deprivation therapy: A retrospective case–control study
2023 · Ali T. Arafa, Leah R. Blader, et al. · The Prostate · 3
PDF
Data from Reverse Translation Identifies the Synergistic Role of Immune Checkpoint Blockade and IL15 to Enhance Immunotherapy of Ovarian Cancer
2023 · Martin Felices, Erin Wesley, et al.
A tri-specific killer engager against mesothelin targets NK cells towards lung cancer
2023 · Philippa R. Kennedy, Daniel A. Vallera, et al. · Frontiers in Immunology · 21
Reverse Translation Identifies the Synergistic Role of Immune Checkpoint Blockade and IL15 to Enhance Immunotherapy of Ovarian Cancer
2023 · Martin Felices, Erin Wesley, et al. · Cancer Immunology Research · 9
PDF
Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma
2022 · Frank Cichocki, Ryan Bjordahl, et al. · Nature Communications · 82
PDF
Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies
2022 · Frank Cichocki, Sjoukje J. C. van der Stegen, et al. · Blood · 93
Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer
2022 · Xiaolei Shi, Abderrahman Day, et al. · npj Precision Oncology · 24
PDF
TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity
2022 · Michael F Kaminski, Laura Bendzick, et al. · Journal for ImmunoTherapy of Cancer · 23
PDF
Dual antigen–targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia
2022 · Frank Cichocki, Jodie P. Goodridge, et al. · Blood · 85
PDF
Balanced engagement of activating and inhibitory receptors mitigates human NK cell exhaustion
2022 · Jacob A. Myers, Dawn Schirm, et al. · JCI Insight · 62
PDF
Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer
2022 · Philippa R. Kennedy, Martin Felices, et al. · Stem Cell Research & Therapy · 49
PDF
CMV Triplex Vaccine to Enhance Adaptive NK and T-cell Reconstitution After Autologous Hematopoietic Cell Transplantation
2022 · Armin Rashidi, Corinna La Rosa, et al. · Transplantation and Cellular Therapy · 8
Human cytomegalovirus alters immune cell profile with potential implications for patient survival in head and neck cancer
2022 · Heather H Nelson, Emma Contestabile, et al. · Carcinogenesis · 6
Chondroitin sulfate proteoglycan 4, a targetable oncoantigen that promotes ovarian cancer growth, invasion, cisplatin resistance and spheroid formation
2021 · Jianbo Yang, Qianjin Liao, et al. · Translational Oncology · 18
PDF
Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy
2021 · Melissa M. Berrien-Elliott, Michelle Becker-Hapak, et al. · Blood · 110
Year
Topic